Optimising a Regional Faecal Calprotectin Pathway in NENC

09/10/2018 1:00 pm @ Durham County Cricket Club

The new Faecal Calprotectin Pathway was introduced by Dr James Turvill, Consultant Gastroenterologist at York Teaching Hospitals NHS Foundation Trust. Rolled out Nationally, this programme has the potential of ultimately affecting 322,000 patients a year and can save £15M of NHS costs over two years.

Yorkshire & Humber AHSN has successfully supported the rollout of the new pathway across seven Clinical Commissioning Groups (CCGs). Use of the new pathway in the region has resulted in a reduction in new hospital

Event Aims

The aims of the event are to increase the awareness and visibility of the National collaborative project.

A detailed agenda will be circulated shortly.

Why Attend?

Calprotectin testing benefits

For the GP:

  • Assists diagnosis
  • Clear process

For the trust:

  • Alleviates waiting lists
  • Increased pathology opportunities

For the CCG:

  • Financial savings

For the patient:

  • Accelerates diagnosis
  • Only referred if required

What is Faecal Calprotectin?

Faecal Calprotectin is an innovative diagnostic test that supports GPs in discriminating between irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Early identification of patients with IBD is enabling quicker referral to the expert secondary care needed to diagnose and manage their condition effectively.

It also means that patients with IBS are not unnecessarily referred to secondary care and do not have to undergo invasive investigations (such as colonoscopies) resulting in an improved patient experience, cost savings and better use of NHS clinical resources.As distinguishing between IBS and IBD is difficult, as many as 19 out of 20 patients are unnecessarily referred to secondary care, which often includes an invasive colonoscopy.

 

Event Details